15-Year safety check for experimental cell therapy
NCT ID NCT07577583
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks 32 people who received Azer-Cel, an experimental cell therapy for B-cell related autoimmune diseases, to monitor long-term safety for up to 15 years. Participants are checked for serious side effects and disease changes. The goal is to understand risks over time, not to test new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MEDIATED AUTOIMMUNE DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.